EP0271521A4 - Compositions a base de lipopolysaccharides et de facteurs naturels dans la therapie antitumorale et procede de traitement. - Google Patents

Compositions a base de lipopolysaccharides et de facteurs naturels dans la therapie antitumorale et procede de traitement.

Info

Publication number
EP0271521A4
EP0271521A4 EP19870903576 EP87903576A EP0271521A4 EP 0271521 A4 EP0271521 A4 EP 0271521A4 EP 19870903576 EP19870903576 EP 19870903576 EP 87903576 A EP87903576 A EP 87903576A EP 0271521 A4 EP0271521 A4 EP 0271521A4
Authority
EP
European Patent Office
Prior art keywords
lps
tumor
tnf
agent
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19870903576
Other languages
German (de)
English (en)
Other versions
EP0271521A1 (fr
Inventor
Michael K Hoffmann
Myung Chun
Ulrich Hammerling
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Sloan Kettering Institute for Cancer Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sloan Kettering Institute for Cancer Research filed Critical Sloan Kettering Institute for Cancer Research
Publication of EP0271521A1 publication Critical patent/EP0271521A1/fr
Publication of EP0271521A4 publication Critical patent/EP0271521A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Definitions

  • SUMMARY Lipopolysaccharide or variants thereof can be used together with such anti-tumor agents as exogenous TNF as effective anti-tumor agents at non-toxic levels.
  • Inhibitors such as indomethacin which block agents, such as prostaglandin which act against immune system activation or agents which act as against suppressor cell activation such as cyclophosphamide can be used as well.
  • Fig. 1 shows synergism in causing necrosis and regression of tumors with LPS and TNF, also with TNF and LPS with INDO (Indomethacin).
  • Fig. 2 shows correlation between tumor necrosis and subsequent regression of tumors.
  • Fig. 1 Synergism between TNF and LPS is causing necrosis and regression of tumor transplants in mice. Animals were treated in addition to TNF and LPS with INDO.
  • Fig. 2 Correlation between tumor necrosis and subsequent regression of tumors, the data obtained with LPS (0) relates the degrees of necrosis in individual mice to the regression of the same tumors. In the experiments with TNF we had not assessed individual mice for necrosis and regression but only groups of identically treated animals. The percent of tumor regression in these animals was related to the group's average degree of necrosis.
  • LPS Lipopolysaccharide
  • LPS has long been known to elicit anti-tumor reaction in experimental animals and man. LPS causes acute partial necrosis of certain murine and human tumor transplants in mice and allows one third of the treated animals to completely reject the tumor. The response can be divided into two phases, an early non-immunologic necrosis phase and a subsequent immunologic rejection phase.
  • TNS tumor necrosis serum
  • TNF is a very efficient inducer of tumor necrosis but is also very toxic to animals. LPS-induced shock seems to be mediated by TNF (B. Beutler et al, Nature 316:552-554, 1985). For the cure of a tumor a mouse seems to have to pay a smaller penalty on toxicity when TNF is administered within TNS than when administered in purified form. TNF kills tumor cells in tissue culture whereas LPS has no effect on cultured tumor cells directly. Our findings suggest LPS acts on tumors through different pathways only one of which is mediated by TNF. In combination the different defense systems are more effective than each by itself. TNS contains other factors which affect the fate of tumors. The increased presence of IL-1 or IL-2 like factors and; of interferon has been identified and indirect evidence suggests the presence of other, as yet unidentified factors.
  • TNS has been found to stimulate the activity of NK cells, a cell that kills tumor cells on contact. It induces also the production of substances such as prostaglandins which paralyze the defense capacity of the tumor host.
  • Interleukin 1 IL-1
  • IL-1 Interleukin 1
  • LPS-reactive macrophages facilitates the activation of lymphocytes which are the carriers of the immunological response against tumors.
  • IL-1 facilitates the recruitment of lymphocytes, causes them to produce lymphokines which participate in the process of the immune response (such as IL-2 and TRF) and is therefore essential for the generation of effector cells which produce either antibodies to tumor associated surface membrane structures or which seek out tumor cells via these membrane antigens and kill them.
  • lymphokines also initiate downregulatory mechanisms which block the immune response. This downregulatory pathway is mediated by cells called suppressor cells, of which suppressor T-cells are the most prominent.
  • LPS can be viewed as inducing reactions that inhibit malignant growth (TNF production, enhancement of immune function) and reactions which favor malignant growth (immune suppression). It would appear, that effective immunotherapy must be designed to support the former reaction and to curb the latter.
  • Our laboratory has identified negative feedback responses which favor tumor growth and we have demonstrated that these feedback mechanisms can be controlled leading to substantial improvement of tumor rejection.
  • Another relevant objective of immunotherapy is the least possible damage caused to the treated tumor host, that is to say low toxicity to the host.
  • Tumor necrosis factor is a highly toxic molecule and its therapeutic dose in mice and humans is limited by its lethal effects. This laboratory has established a treatment regimen in which TNF can be applied in low (not toxic) doses in conjunction with other reagents in non toxic doses.
  • LPS itself is a good candidate to complement TNF function since LPS induces in the host the release of several lymphokines such as IL-1, IFN, IL-2 and those not identified as yet which may replace LPS.
  • LPS presumably through mediators such as IFN causes increased production of prostaglandins (PG) in the tumor host.
  • PG prostaglandins
  • PG inhibits the function of the immune system (including NK cell activity).
  • Inhibition of PG synthesis with Indomethacin increases the tumor rejection induced by TNF and LPS from 30 to 60 percent.
  • LPS causes the generation of suppressor cells.
  • Suppressor cell activity can be inhibited by administration of cyclophosphamide and this drug given together with TNF, LPS and INDO increases tumor rejection in mice up to 100%.
  • LPS Bacterial lipopolysaccharide
  • TNF tumor necrosis factor
  • TNF tumor necrosis factor
  • Effective therapeutic use of TNF is limited, however, by its toxicity.
  • We show here, that the efficacy of TNF can be substantially increased by combining its application with low doses of LPS.
  • Our data suggests that LPS exerts its anti-tumor effects by engaging more than one defense mechanism.
  • Characteristic for the activation of a biological system is a concommitant induction of negative feedback mechanisms which antagonize the initial stimulus. Interference with the negative feedback response may substantially increase biological reactions.
  • LPS prostaglandin E
  • PGE prostaglandin E
  • analogues of LPS in low doses to stimulate the systems to produce natural anti-tumor factors.
  • Meth A tumors were maintained in BALB/c mice by weekly passages. For transplants, 10 cells/0.2 ml, were injected intradermally into two sites of the shaved abdominal skin of (BALB/c x C57BL/6) F1 mice with a 30 gauge needle. The grade of tumor necrosis was scored 48 hours after LPS treatment in a grading system consisting of grades 0,1,2 and 3 according to Carswell et al. Proc.Natl. Acad. Sci., Supra. Tumor rejections were scored four weeks later. Grade 3 reflects total or near total necrosis of the tumor, grade 2 covers necrosis areas down to approximately one-half of the tumor, and grade 1, covers all necrosis areas smaller than one-half of the tumor.
  • BALB/c mice and (BALB/c x C57BL/6) F1 mice were purchased from Jackson Laboratories, Bar Harbor, Maine.
  • TNF or LPS was injected intraveneously. Indomethacin (100 ug/animal) was injected intraveneously together with LPS and/or TNF and subsequently added to the drinking water (20 ug/ml). Cyclophosphamide (30 mg/kg) was injected interperitoneally. Freshly prepared BALB/c mouse serum was injected intraveneously twice, two and 5 days after LPS injection.
  • TNF is an effective inducer of tumor necrosis but its therapeutic dose range is small. Substantial degrees of necrosis can be achieved with the injection of 10 ug TNF. There is a rapid decline of necrosis at lower doses. Higher doses were toxic and not administered here. LPS, in a non-toxic dose range, is a less potent inducer of tumor necrosis than purified TNF. Added together, however, the two drugs synergize. They cause a more effective tumor necrotization together than either one of the two substances alone.
  • LPS lymphocytes
  • IFN interferon
  • NK cell activity G. Trinchieri, et al, J. Exp. Med., 147: 1314-1332, 1978; M. Chun et al, J. Exp. Med., 150: 426-431, 1979; M. Chun et al, J. Immunol., 12:331-334, 1981.
  • IFN interferon
  • Another factor is interleukin-1, a mediator that stimulates the antigen dependent response of lymphocytes (M.K.
  • IFN activates NK cells.
  • NK cell activation contributes to the response of tumor-bearing mice to LPS, and studied the activation of NK cells in vitro.
  • PGE prostaglandin E
  • the production of PGE may be blocked with indomethacin (INDO) (H.R. Strausser et al, Int. J. Cancer, 15:724-730, 1975) and suppression of PGE production by INDO increases NK cell activation by IFN 5-50 times (M. Chun et al, J. Scan. Immunol., Supra).
  • INDO indomethacin
  • LPS alone.
  • the degree of necrosis induced with LPS is also increased by treatment of tumor bearing mice with INDO.
  • LPS may also stimulate antigen-specific lymphocyte reactions through the release of IL-1 (M.K. Hoffman et al. Nature, 263:416-417, 1976; S.K. Durmm et al. Am. Rev. Immunol., 3 : 262-368 , 1985; M.K. Hoffman et al, J. Immunol., 122:1371-1375, 1979).
  • An immune response of T lymphocytes against tumor-associated antigens has been described by Berendt et al. as a consequence of LPS treatment (M.J. Berendt et al, J. Exp. Med., 148:1550-1559, 1978; M.J. Berendt et al, J. Exp.
  • Cyclophosphamide (Cy) injected two days after LPS and INDO allows almost all experimental animals to reject their tumors.
  • Cy was chosen to delay injection of Cy as compared to the injection of LPS and INDO because preliminary experiments had shown Cy to interfere with the formation of tumor necrosis induced by LPS.
  • TNF tumor necrosis factor
  • LPS-induced tumor regression are two distinct phases of LPS mediated anti-tumor activities (M.J. Berendt et al, J. Exp. Med., 148:1550-1559, 1978; L.J. Old et al, Current enigmas in cancer research. Lectures, Series 67:273-315, Academic Press, New York and London, 1973), it would appear that TNF mediates only the early phase of tumor necrosis induction.
  • TNF may not be the only factor in LPS-induced TNS to account for effective necrotization of tumors because TNF synergizes with LPS also in causing tumor necrosis. It is unlikely that this can be attributed to the release of additional TNF. LPS causes necrosis only in rather high concentrations but synergizes with TNF in low concentrations. This would suggest that in order to produce TNF, LPS is required in high doses, while in low doses it causes the release of factors that synergize with TNF (LPS itself does not act directly on tumor cells) (E.A. Carswell et al, Proc. Nat. Acad. Sci. USA., 72:3666-3670, 1975).
  • LPS is thus an extremely effective anti-tumor therapeutic substance in mammals as shown against Meth-A tumor transplants in mice. Its main disadvantage, its toxicity, seems to be related to the production of TNF (B. Beutler et al, Nature, 316:552-554, 1985) whose sufficient production (judged by the degree of necrosis achieved) requires high doses of LPS. When TNF is used from an external source much lower doses of LPS are needed to complement TNF action.
  • LPS provides an example as to how these defense systems may interact to achieve an optimized attack against malignancies and the study of LPS action may help in designing new strategies in the treatment of malignancies by activating the body's means of defense in a concerted fashion.
  • this method may prove effective when used together with other chemotherapeutic agents or chemical equivalents or variants of the natural agents induced by LPS.
  • purified natural TNF, IL-I, IL-2 or IFN may be used or recombinant material.
  • combination therapy between LPS and factors whose: release it induces such as TNF, IL-1, IL-2 or IFN is indicated as is combination therapy between factors whose release LPS causes: TNF, IL-1, IL-2, IFN.
  • Combination therapy involves direct (TNF) effects on tumor cells and indirect effects (mediated by the immune system). It does not relate to a combined effect of different factors directly on tumor cells such as seen in the synergism between TNF and IFN on L cells in vitro.
  • TNF effects may also be shown by other factors with the ability to cause necrosis of tumor cells and which may be released by different cell types.
  • LPS effects may also be shown by other microbial or non microbial products which cause the release of immunoregulatory factors in mammals.
  • chemotherapeutic agents or natural factors which block the negative feedback inhibition against immune system activation.
  • Indomethacin is only one example from a group of prostaglandin inhibitors such as aspirin or Voltaren (Ciba-Geigy Co., Basel, Switzerland).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Des lipopolysaccharides bactériens (LPS) peuvent être utilisés pour induire la libération dans le sérum de facteurs permettant le rejet de tumeurs et augmentant l'efficacité des agents antitumoraux ajoutés. Cela permet d'utiliser le TNF, en combinaison avec le LPS ou d'autres facteurs induits par le LPS, à moindres doses non toxiques pour provoquer le rejet de la tumeur. Ces facteurs peuvent être combinés dans une thérapie antitumorale avec d'autres agents chimiothérapeutiques tels que l'indométhacine ou le cyclophosphamide ou des agents naturels tels que le facteur thrombocitaire (4) qui bloquent les réactions négatives supprimant le système immunitaire, stimulant ainsi la résistance du corps à la thérapie.
EP19870903576 1986-05-09 1987-05-07 Compositions a base de lipopolysaccharides et de facteurs naturels dans la therapie antitumorale et procede de traitement. Withdrawn EP0271521A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86156686A 1986-05-09 1986-05-09
US861566 1986-05-09

Publications (2)

Publication Number Publication Date
EP0271521A1 EP0271521A1 (fr) 1988-06-22
EP0271521A4 true EP0271521A4 (fr) 1989-11-14

Family

ID=25336155

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19870903576 Withdrawn EP0271521A4 (fr) 1986-05-09 1987-05-07 Compositions a base de lipopolysaccharides et de facteurs naturels dans la therapie antitumorale et procede de traitement.

Country Status (4)

Country Link
EP (1) EP0271521A4 (fr)
JP (1) JPS63503308A (fr)
AU (1) AU7397887A (fr)
WO (1) WO1987006830A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4844895A (en) * 1985-11-01 1989-07-04 New York University Composition containing a peptide fragment of platelet factor four and method for restoring suppressed immune responses
WO1988002632A1 (fr) * 1986-10-16 1988-04-21 President And Fellows Of Harvard College Combinaisons de facteurs de necroses de tumeurs et d'agents anti-inflammatoires, et procedes de traitement de maladies malignes et non malignes
US20070025958A1 (en) 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
CA2950109C (fr) 2000-10-27 2019-02-19 John W. Hadden Immunotherapie vaccinale pour patients immunodeprimes
TW200303759A (en) * 2001-11-27 2003-09-16 Schering Corp Methods for treating cancer
CA2472578A1 (fr) * 2002-01-24 2003-07-31 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combinaison anticancereuse et son utilisation
DE60304989T2 (de) * 2003-02-18 2007-03-29 Clinique La Prairie Research S.A. Zusammensetzungen enthaltend fötales Hämoglobin und bakterielles Endotoxin und fakultativ zusätzliche fötale Leberkomponenten
US20050059613A1 (en) * 2003-07-08 2005-03-17 Bahram Memarzadeh Compositions and methods for the enhanced uptake of therapeutic agents through the bladder epithelium
EP1881080A1 (fr) 2006-07-18 2008-01-23 Institut Gustave Roussy Troubles du récepteur de type toll (TLR)-4 et relatives applications biologiques
AU2008329741B2 (en) 2007-11-28 2013-09-12 Irx Therapeutics, Inc. Method of increasing immunological effect
WO2010132867A1 (fr) 2009-05-15 2010-11-18 Irx Therapeutics, Inc. Immunothérapie par vaccin
US9333238B2 (en) 2009-12-08 2016-05-10 Irx Therapeutics, Inc. Method of immunotherapy for treament of human papillomavirus infection

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH643138A5 (de) * 1983-08-29 1984-05-30 Mepha Ag Indomethacin enthaltende, gelartige salbe.

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
No further relevant documents have been disclosed. *
See also references of WO8706830A1 *

Also Published As

Publication number Publication date
EP0271521A1 (fr) 1988-06-22
AU7397887A (en) 1987-12-01
WO1987006830A1 (fr) 1987-11-19
JPS63503308A (ja) 1988-12-02

Similar Documents

Publication Publication Date Title
Rosenberg et al. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.
US5756085A (en) Use of interleukin-12 to prevent graft versus host disease
RU2153332C2 (ru) Способ сенсибилизации раковых клеток к лизису, опосредованному клетками-киллерами
RU2195946C2 (ru) Противоопухолевые терапевтические средства, включающие комбинацию экстракта хряща и антинеопластического агента, обеспечивающие высокую эффективность действия при низких токсических побочных эффектах
WO1987006830A1 (fr) Compositions a base de lipopolysaccharides et de facteurs naturels dans la therapie antitumorale et procede de traitement
US5961969A (en) Stable circulating histamine levels
Patchen et al. Betafectin" PGG-glucan
EP0303687B1 (fr) Compositions pour ameliorer les therapies adcc
Chihara Preclinical evaluation of lentinan in animal models
JP4371437B2 (ja) 悪性腫瘍の治療方法
Chun et al. Combination immunotherapy of cancer in a mouse model: synergism between tumor necrosis factor and other defense systems
Lala et al. Eradication of spontaneous and experimental adenocarcinoma metastases with chronic indomethacin and intermittent IL‐2 therapy
Kleinerman et al. Effect of L-phenylalanine mustard, adriamycin, actinomycin D, and 4′-(9-acridinylamino) methanesulfon-m-anisidide on naturally occurring human spontaneous monocyte-mediated cytotoxicity
Wu et al. Radioprotection of C3H mice by recombinant human interleukin-1α
Bloksma et al. Synergistic action of human recombinant tumor necrosis factor with endotoxins or nontoxic poly A: U against solid Meth A tumors in mice
佐々木琢磨 et al. Antitumor activity and immunomodulatory effect of glycoprotein fraction from scallop Patinopecten yessoensis.
Saijo et al. In vivo and in vitro effects of Nocardia rubra cell wall skeleton on natural killer activity in mice
Matsumori et al. Immunomodulating therapy in experimental myocarditis
JPS62263127A (ja) 自己由来のｌａｋ細胞、インタ−ロイキン−２、及びオルニチンデカルボキシラ−ゼ阻害剤による腫瘍の処置
JPH09510737A (ja) 化学療法剤を増強するためのｉｌ−４の使用
Krosnick et al. Studies of the mechanisms of toxicity of the administration of recombinant tumor necrosis factor α in normal and tumor-bearing mice
Schindler et al. Stimulatory effects of muramyl dipeptide and its butyl ester derivative on the proliferation and activation of macrophages in vitro
Kedar et al. Suppression by tumor growth of T cell growth factor production in mouse lymphoid cell cultures
Jones et al. Absence of generalized immunosuppression in C57BL/6J mice implanted with Lewis T241 fibrosarcoma or Lewis lung carcinoma
CN114848681A (zh) 一种免疫治疗组合物及其用途

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17P Request for examination filed

Effective date: 19880509

A4 Supplementary search report drawn up and despatched

Effective date: 19891114

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19900117

RIN1 Information on inventor provided before grant (corrected)

Inventor name: CHUN, MYUNG

Inventor name: HOFFMANN, MICHAEL, K.

Inventor name: HAMMERLING, ULRICH